Inconsistencies among a growing number of genetic databases could lead to misdiagnoses of genetic disorders by health care providers, according to a study that appears in Cytogentic and Genome Research.

A review of Perth-based Phylogica's (ASX:PYC) Phylomer technology has been published in the February issue of Nature Biotechnology. [ + ]

Australian and European authorities have eased the regulatory pathway for Resonance Health (ASX:RHT), by endorsing quality assurance systems for the Perth-based firm's FerriScan technology. [ + ]

A new AUD$20 million agricultural biotech centre will be opened by Victorian premier Steve Bracks this Wednesday. [ + ]

CogState (ASX:CGS) is to provide cognition testing services to a European food products company in a contract worth more than AUD$400,000. [ + ]

The Australian Drug Evaluation Committee has recommended to the TGA that Sydney-based drug developer Pharmaxis' (ASX:PXS) first product, the asthma diagnostic and treatment management tool Aridol, be registered for sale in Australia. [ + ]

The ASX has issued a 'please explain' to Brisbane-based Analytica (ASX:ALT), querying whether the company will have enough cash to last it past the next quarter. [ + ]

Two UCLA studies have shown that newborn screening for Severe Combined Immunodeficiency (SCID) a rare, treatable disorder of the immune system commonly known as 'bubble boy disease' is both cost-effective and could be done accurately using a two tiered testing method.

Proteome Systems has announced a collaboration with Prince Henry's Institute Medical Research (PHIMR) to combine their IP and expertise in ovarian cancer for the discovery and development of novel diagnostic markers.

Perth-based bio-nanotech company pSivida's (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) Retisert will be co-promoted in the US by Novartis Ophthalmics. [ + ]

Melbourne-base Solagran has been granted Russian approval to register Ropren, the finished form of Bioeffective R, as a new medicine for the treatment for chronic liver disease. [ + ]

BioTech Capital (ASX:BTC) has reduced its shareholding in Clinical Cell Culture (ASX:CCE, C3) from about 19 per cent to 12 per cent. [ + ]

Auckland-based BrainZ (ASX:BZI) has established its US clinical support team and headquarters. [ + ]

Researchers have developed a blood test that detects the presence of fragments of mutated genes that are present in colon cancer cells. Their pilot studies provide the basis for diagnostic assays for cancer that could allow physicians to detect rumours at an early stage.

University of Sydney researchers claim to have achieved almost perfect discrimination between two major forms of heart disease from patients' blood samples, using Sydney firm Medsaic's proprietary DotScan technology. [ + ]